Archives of Gynecology and Obstetrics

, Volume 300, Issue 5, pp 1167–1175 | Cite as

The clinical benefits of hormonal treatment for LG-ESS: a meta-analysis

  • Ran Cui
  • Guangming Cao
  • Huimin BaiEmail author
  • Zhenyu ZhangEmail author



To evaluate the clinical benefits of hormonal treatment for patients with low-grade endometrial stromal sarcoma (LG-ESS) by reviewing the published literature and performing a meta-analysis.


Correlational studies related to hormonal treatment for LG-ESS patients were collected by searching the PubMed, EMBASE, and Cochrane databases up to December 2018. Eligible studies were selected based on inclusion and exclusion criteria. The main inclusion criteria included: original studies with definite diagnoses of LG-ESS that evaluated the clinical benefits of hormonal treatment, studies with at least 10 cases, and studies published in English. Reviews, case reports, letters, comments or conference abstracts, studies without sufficient data and overlapping or republished studies were excluded. The study quality was evaluated, and pooled relative risks and 95% confidence intervals were calculated using Review Manager 5.3.


A total of 10 retrospective studies were included. The NOS stars of the 10 studies ranged from 7 to 9 points, which was considered to be of high quality. Recurrence and death information was provided in 9 and 6 studies, respectively. The overall pooled RR for recurrence was 0.66 (95% CI 0.47–0.94), which indicated that hormonal treatment was effective at reducing the recurrence risk (P = 0.02). The overall pooled RR for death was 0.81 (95% CI 0.59–1.12), which showed that hormonal treatment had little effect in prolonging overall survival (P = 0.20). Stratified analysis showed that compared with the group without any adjuvant treatments, hormonal treatment alone significantly decreased the risk of recurrence (P = 0.02), while hormonal treatment had no significant effects on overall survival (P = 0.38). Another subgroup analysis indicated that for stage I–II patients, hormonal treatment could significantly decrease the risk of recurrence (P = 0.02) but could not influence overall survival (P = 0.87). However, for stage III–IV patients, hormonal treatment had little benefit both in reducing the recurrence risk and prolonging overall survival (P = 0.49/0.08). Egger’s and Begg’s test showed that the publication bias for the literature was satisfactorily controlled.


Adjuvant hormonal treatment should be considered as a feasible adjuvant therapy for reducing the recurrence risk of patients with LG-ESS while bearing little benefit on overall survival.


Adjuvant hormonal treatment Low-grade endometrial stromal sarcoma Recurrence Overall survival Meta-analysis 


Authors' contribution:

The present study is contributed by Ran Cui, Guangming Cao, Huimin Bai, and Zhenyu Zhang. RC: data collection and analysis, manuscript writing; GMC: data collection and analysis, HMB and ZYZ: protocol development, data management and analysis, and manuscript editing.


This work was supported by the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding-YangFan Project (No.ZYLX201713) and National Natural Science Foundation of China (No. 81972424).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Conklin CM, Longacre TA (2014) Endometrial stromal tumors: the new WHO classification. Adv Anat Pathol 21(6):383–393. CrossRefPubMedGoogle Scholar
  2. 2.
    Rauh-Hain JA, Del Carmen MG (2013) Endometrial stromal sarcoma: a systematic review. Obstet Gynecol 122(3):676–683. CrossRefPubMedGoogle Scholar
  3. 3.
    Yamazaki H, Todo Y, Mitsube K, Hareyama H, Shimada C, Kato H, Yamashiro K (2015) Long-term survival of patients with recurrent endometrial stromal sarcoma: a multicenter, observational study. J Gynecol Oncol 26(3):214–221. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Thiel FC, Halmen S (2018) Low-grade endometrial stromal sarcoma - a review. Oncol Res Treat 41(11):687–692. CrossRefPubMedGoogle Scholar
  5. 5.
    Chu MC, Mor G, Lim C, Zheng W, Parkash V, Schwartz PE (2003) Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol 90(1):170–176CrossRefGoogle Scholar
  6. 6.
    Park JY, Baek MH, Park Y, Kim YT, Nam JH (2018) Investigation of hormone receptor expression and its prognostic value in endometrial stromal sarcoma. Virchows Arch 473(1):61–69. CrossRefPubMedGoogle Scholar
  7. 7.
    Reich O, Regauer S (2004) Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study. Mod Pathol 17(1):104–108. CrossRefPubMedGoogle Scholar
  8. 8.
    Cade TJ, Quinn MA, Rome RM, Polyakov A (2014) Prognostic significance of steroid receptor positivity and adjuvant progestogen use in endometrial stromal sarcoma. Aust N Z J Obstet Gynaecol 54(5):453–456. CrossRefPubMedGoogle Scholar
  9. 9.
    Yoon A, Park JY, Park JY, Lee YY, Kim TJ, Choi CH, Bae DS, Kim BG, Lee JW, Nam JH (2014) Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: a multicenter review of 114 cases. Gynecol Oncol 132(1):70–75. CrossRefPubMedGoogle Scholar
  10. 10.
    Amant F, De Knijf A, Van Calster B, Leunen K, Neven P, Berteloot P, Vergote I, Van Huffel S, Moerman P (2007) Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma. Br J Cancer 97(9):1194–1199. CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Landreat V, Paillocher N, Catala L, Foucher F, Descamps P, Leveque J (2008) Low-grade endometrial stromal sarcoma of the uterus: review of 10 cases. Anticancer Res 28(5b):2869–2874PubMedGoogle Scholar
  12. 12.
    Beck TL, Singhal PK, Ehrenberg HM, Rose PG, Lele SB, Krivak TC, McBee WC Jr (2012) Endometrial stromal sarcoma: analysis of recurrence following adjuvant treatment. Gynecol Oncol 125(1):141–144. CrossRefPubMedGoogle Scholar
  13. 13.
    Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE (2018) adjuvant hormonal therapy for low-grade endometrial stromal sarcoma. Reprod Sci 193:01. CrossRefGoogle Scholar
  14. 14.
    Zhou J, Zheng H, Wu SG, He ZY, Li FY, Su GQ, Sun JY (2015) Influence of different treatment modalities on survival of patients with low-grade endometrial stromal sarcoma: a retrospective cohort study. Int J Surg Lond Engl 23(Pt A):147–151. CrossRefGoogle Scholar
  15. 15.
    Seagle BLL, Shilpi A, Buchanan S, Goodman C, Shahabi S (2017) Low-grade and high-grade endometrial stromal sarcoma: a national cancer database study. Gynecol Oncol 146(2):254–262. CrossRefPubMedGoogle Scholar
  16. 16.
    Stewart LE, Beck TL, Giannakopoulos NV, Rendi MH, Isacson C, Goff BA (2018) Impact of oophorectomy and hormone suppression in low grade endometrial stromal sarcoma: a multicenter review. Gynecol Oncol 149(2):297–300. CrossRefPubMedGoogle Scholar
  17. 17.
    Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRefGoogle Scholar
  18. 18.
    Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Urgesi A, Lissoni A, Losa G, Fanucchi A (1996) Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol 63(2):247–253. CrossRefPubMedGoogle Scholar
  19. 19.
    Huang KT, Chen CA, Tseng GC, Chen TM, Cheng WF, Hsieh CY (1996) Endometrial stromal sarcoma of twenty cases. Acta Obstet Gynecol Scand 75(6):551–555CrossRefGoogle Scholar
  20. 20.
    Bai H, Yang J, Cao D, Huang H, Xiang Y, Wu M, Cui Q, Chen J, Lang J, Shen K (2014) Ovary and uterus-sparing procedures for low-grade endometrial stromal sarcoma: a retrospective study of 153 cases. Gynecol Oncol 132(3):654–660. CrossRefPubMedGoogle Scholar
  21. 21.
    Cui R, Yuan F, Wang Y, Li X, Zhang Z, Bai H (2017) Clinicopathological characteristics and treatment strategies for patients with low-grade endometrial stromal sarcoma. Medicine 96(15):e6584. CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Ali RHA-Ohoo, Rouzbahman M Endometrial stromal tumours revisited: an update based on the 2014 WHO classification. (1472–4146 (Electronic)) Google Scholar
  23. 23.
    Amant F, Floquet A, Friedlander M, Kristensen G, Mahner S, Nam EJ, Powell MA, Ray-Coquard I, Siddiqui N, Sykes P, Westermann AM, Seddon B (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma. Int J Gynecol Cancer 24(9):S67–S72. CrossRefPubMedGoogle Scholar
  24. 24.
    Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I (2009) Clinical management of uterine sarcomas. Lancet Oncol 10(12):1188–1198. CrossRefPubMedGoogle Scholar
  25. 25.
    Soft tissue and visceral sarcomas (2014) ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:102–112. CrossRefGoogle Scholar
  26. 26.
    Barney B, Tward JD, Skidmore T, Gaffney DK (2009) Does radiotherapy or lymphadenectomy improve survival in endometrial stromal sarcoma? Int J Gynecol Cancer 19(7):1232–1238. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyBeijing Chao-Yang Hospital, Capital Medical UniversityBeijingChina

Personalised recommendations